EGFR and metastatic malignant neoplasm in the spinal cord: However, additional analyses using clinical data would be needed to confirm our findings to account for the longer available follow‐up time for the first‐ and second‐EGFR TKI cohorts and for the timing of the brain or spinal cord metastasis diagnosis during follow‐up since diagnoses occurring close to the index date may suggest baseline metastatic disease that was not coded.